The Influence of Visceral Adiposity on Overall Survival: Exploring "Obesity Paradox" Among Hepatocellular Carcinoma Patients Who Receiving Immunotherapy.

IF 4.2 3区 医学 Q2 ONCOLOGY Journal of Hepatocellular Carcinoma Pub Date : 2024-06-24 eCollection Date: 2024-01-01 DOI:10.2147/JHC.S453262
Yanzhao Zhou, Jingzhong Ouyang, Hongcai Yang, Zhengzheng Wang, Yi Yang, Qingjun Li, Haitao Zhao, Jinxue Zhou, Qiang Li
{"title":"The Influence of Visceral Adiposity on Overall Survival: Exploring \"Obesity Paradox\" Among Hepatocellular Carcinoma Patients Who Receiving Immunotherapy.","authors":"Yanzhao Zhou, Jingzhong Ouyang, Hongcai Yang, Zhengzheng Wang, Yi Yang, Qingjun Li, Haitao Zhao, Jinxue Zhou, Qiang Li","doi":"10.2147/JHC.S453262","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The impact of visceral adiposity on overall survival (OS) in hepatocellular carcinoma (HCC) receiving immunotherapy was unclear. We aimed to determine how visceral adiposity affected OS and explore the interrelationships between visceral adiposity, body mass index (BMI), and other body compositions.</p><p><strong>Patients and methods: </strong>Data from three centers were retrospectively analyzed. Skeletal muscle index (SMI), skeletal muscle density (SMD), visceral adipose tissue index (VATI), and subcutaneous adipose tissue index (SATI) were used to define each body composition. The BMI subgroups included the underweight, the normal weight, and the obesity. The Log rank test compared survival curves calculated by the Kaplan-Meier method. The relationships between body compositions and BMI with OS were examined using Cox proportional risk regression models.</p><p><strong>Results: </strong>A total of 305 patients who met the criteria were included. Patients with low VATI had significantly worse OS (<i>P</i> = 0.001). The protections of VATI (<i>P</i> = 0.011) on OS were independent of covariates. However, after additional adjustment of SMI, the effect of VATI on OS disappeared (<i>P</i> = 0.146), but the effect of SMD on OS did not (<i>P</i> = 0.021). BMI has a significant U-shaped relationship with OS, and the effect of BMI on OS equally disappeared after additional adjustment by SMI.</p><p><strong>Conclusion: </strong>This study first demonstrated that high VATI and mid-level BMI were protective for the survival of patients with HCC receiving immunotherapy. Skeletal muscle status (including SMI and SMD) may be the better predictor for outcomes of patients with HCC receiving immunotherapy.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11212812/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S453262","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The impact of visceral adiposity on overall survival (OS) in hepatocellular carcinoma (HCC) receiving immunotherapy was unclear. We aimed to determine how visceral adiposity affected OS and explore the interrelationships between visceral adiposity, body mass index (BMI), and other body compositions.

Patients and methods: Data from three centers were retrospectively analyzed. Skeletal muscle index (SMI), skeletal muscle density (SMD), visceral adipose tissue index (VATI), and subcutaneous adipose tissue index (SATI) were used to define each body composition. The BMI subgroups included the underweight, the normal weight, and the obesity. The Log rank test compared survival curves calculated by the Kaplan-Meier method. The relationships between body compositions and BMI with OS were examined using Cox proportional risk regression models.

Results: A total of 305 patients who met the criteria were included. Patients with low VATI had significantly worse OS (P = 0.001). The protections of VATI (P = 0.011) on OS were independent of covariates. However, after additional adjustment of SMI, the effect of VATI on OS disappeared (P = 0.146), but the effect of SMD on OS did not (P = 0.021). BMI has a significant U-shaped relationship with OS, and the effect of BMI on OS equally disappeared after additional adjustment by SMI.

Conclusion: This study first demonstrated that high VATI and mid-level BMI were protective for the survival of patients with HCC receiving immunotherapy. Skeletal muscle status (including SMI and SMD) may be the better predictor for outcomes of patients with HCC receiving immunotherapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
内脏脂肪对总生存期的影响:探索接受免疫疗法的肝细胞癌患者的 "肥胖悖论"。
目的:内脏脂肪对接受免疫疗法的肝细胞癌(HCC)患者总生存期(OS)的影响尚不清楚。我们旨在确定内脏脂肪对OS的影响,并探讨内脏脂肪、体重指数(BMI)和其他身体成分之间的相互关系:对来自三个中心的数据进行了回顾性分析。采用骨骼肌指数(SMI)、骨骼肌密度(SMD)、内脏脂肪组织指数(VATI)和皮下脂肪组织指数(SATI)来定义各种身体成分。体重指数亚组包括体重不足、体重正常和肥胖。对数秩检验比较了 Kaplan-Meier 法计算的生存曲线。使用 Cox 比例风险回归模型研究了身体成分和 BMI 与 OS 之间的关系:共纳入了 305 名符合标准的患者。低 VATI 患者的 OS 明显较差(P = 0.001)。VATI对OS的保护作用(P = 0.011)与协变量无关。然而,在对 SMI 进行额外调整后,VATI 对 OS 的影响消失了(P = 0.146),但 SMD 对 OS 的影响没有消失(P = 0.021)。BMI与OS呈明显的U形关系,BMI对OS的影响在额外调整SMI后同样消失:本研究首次证明,高 VATI 和中等水平的 BMI 对接受免疫疗法的 HCC 患者的生存具有保护作用。骨骼肌状态(包括 SMI 和 SMD)可能是预测接受免疫疗法的 HCC 患者预后的更好指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.50
自引率
2.40%
发文量
108
审稿时长
16 weeks
期刊最新文献
Predicting Pathological Response of Neoadjuvant Conversion Therapy for Hepatocellular Carcinoma Patients Using CT-Based Radiomics Model. Circulating Biomarkers Predict Immunotherapeutic Response in Hepatocellular Carcinoma Using a Machine Learning Method. Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs). A Comparative Study of Surgical Approaches for Hepatocellular Carcinoma: Conversion versus Direct Resection. FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1